<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01617135</url>
  </required_header>
  <id_info>
    <org_study_id>CVT-301-002</org_study_id>
    <secondary_id>2012-000181-37</secondary_id>
    <nct_id>NCT01617135</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and &quot;Off&quot; Episodes</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Phase 2 Study of the Safety, Pharmacokinetics and Pharmacodynamics of CVT-310 (Levodopa Inhalation Powder) in Patients With Parkinson's Disease and Motor Response Fluctuations (&quot;Off Episodes&quot;)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acorda Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Acorda Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, efficacy and pharmacokinetics following
      administration of CVT-301 in treatment of &quot;off&quot; episodes in Parkinson's Disease patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment options for patients with motor response fluctuations are limited. Most commonly,
      &quot;off&quot; episodes are managed by adjusting the dose interval of their standard oral medications
      or by self-administration of unscheduled doses of oral Parkinson's medication. Due to the
      variability in levodopa absorption following oral dosing, resumption of motor function is
      unreliable and may be delayed for an hour or more. CVT-301 delivers levodopa using a simple
      inhaler, resulting in rapid increases in levodopa blood levels and is expected to result in
      rapid restoration in motor function for patients experiencing &quot;off&quot; episodes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>change from baseline up to 13 weeks</time_frame>
    <description>Adverse experiences, ECGs, clinical laboratory evaluation, pulmonary function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>3 hours post-dose</time_frame>
    <description>Time to onset of meaningful &quot;on&quot; and &quot;off&quot; states (patient- and examiner-assessed) UPDRS III motor score Tapping test Dyskinesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>3 hours post-dose</time_frame>
    <description>Serial blood draw for determination of plasma concentration-time profile</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Idiopathic Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>CVT-301 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CVT-Low; levodopa inhalation powder (LIP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CVT-301 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CVT-High; levodopa inhalation powder (LIP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled placebo powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Sinemet (carbidopa/levodopa)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open-label oral carbidopa/levodopa (CD/LD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CVT-301</intervention_name>
    <arm_group_label>CVT-301 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Inhaled Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sinemet (carbidopa/levodopa)</intervention_name>
    <arm_group_label>Oral Sinemet (carbidopa/levodopa)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CVT-301</intervention_name>
    <arm_group_label>CVT-301 High Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic Parkinson's Disease (PD) diagnosed between the ages of 30 and 80 years;

          -  Hoehn and Yahr Stage 1-3 in an &quot;on&quot; state;

          -  Require levodopa-containing medication regimen at least 4 times during the waking day;

          -  Experience motor fluctuations with a minimum of 2 hours of average daily &quot;off&quot; time
             per waking day (excluding early morning &quot;off&quot; time) and demonstrate levodopa
             responsiveness;

          -  Are on stable PD medication regimen.

        Exclusion Criteria:

          -  Pregnant or lactating females;

          -  Previous surgery for PD or plan to have stereotactic surgery during the study period;

          -  History of psychotic symptoms requiring treatment, or suicide ideation or attempt
             within last year;

          -  Adequate lung function as measured by spirometry;

          -  Any significant condition, severe concurrent disease, abnormality or finding that
             would make patients unsuitable or may compromise patient safety.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Civitas Clinical Site #6</name>
      <address>
        <city>Petach-Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Civitas Clinical Site #5</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Civitas Clinical Site #4</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Civitas Clinical Site #7</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Civitas Clinical Site #1</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Civitas Clinical Site #3</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Civitas Clinical Site #2</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Serbia</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://foxtrialfinder.michaeljfox.org/</url>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2012</study_first_submitted>
  <study_first_submitted_qc>June 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2012</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Motor fluctuations</keyword>
  <keyword>levodopa</keyword>
  <keyword>inhaled drugs</keyword>
  <keyword>Motor fluctuation (&quot;off episodes&quot;)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

